Herbal Medicine in China: A RMB 1 Trillion Industry and a Policy Priority

Herbal medicine in China in 2025 data

  • China Traditional Chinese Medicine Holdings reported 2025 revenue of RMB 14.74 billion, down 10.7%, and a net loss of RMB 0.46 billion, according to Tiger Brokers.
  • Its concentrated granules segment fell 12.5% to RMB 6.10 billion because of lower prices and volumes under nationwide centralized procurement.
  • TCM finished drugs earned RMB 4.25 billion at a 66.7% gross margin, up 3.1 points.
  • Yunnan Baiyao proposed a total cash dividend of about RMB 4.64 billion, 90.09% of net profit, as shown in its 2025 annual report summary.
  • China TCM Holdings’ R&D spending was RMB 0.51 billion, down 14.2%, while its selling expenses fell 8.6% to RMB 4.95 billion.

Herbal medicine is no longer a niche old-fashioned business. It is a large, regulated industry where state buying rules decide who makes money.

TCM Holdings revenue by segment 2025
Source: China Traditional Chinese Medicine Holdings 2025 results via Tiger Brokers; Daxue Consulting

An ancient system, still in use

The science of herbs is one of the oldest and longest-lasting healing systems in the world, and an unavoidable part of Traditional Chinese Medicine. The first, traces of herbal medicine in China are about 5,000 years old. It is commonly used by Chinese people, and more and more around the world.

  • The first book gathering this knowledge was written in the Ming dynasty by Li Shizhen, and listed around 2,000 ingredients.
  • The latest edition of the Pharmacopoeia of the People’s Republic of China in our early research, from 1990, listed more than 500 herbs and extracts, and nearly 300 complex formulations.
  • In TCM, everything is interconnected. A vital energy, Qi, circulates in the body, and Yin and Yang are its two opposite and complementary forms.
  • More than 400 formulas exist, each with 4 to 12 herbs, taken as decoctions, powders, pills, lotions or syrups.

In most remedies, one or two main ingredients target the problem, while the others support them or direct the formula to a part of the body. Some Herbs are common kitchen items, such as ginger, green tea, cinnamon or garlic, while others, such as peony flowers, ginseng or chrysanthemum, are less known to the public.

Key idea. Key idea. Tradition sells the product, but regulation shapes the profit. In 2025 the winners were companies with branded finished drugs and strong margins, not those with commodity granules.

How the industry is organized today

  • Concentrated granules. The largest segment at China TCM Holdings, with 41.4% of revenue, but a falling margin of 53.8%.
  • Finished drugs. Branded, patented or well known formulas, with a higher 66.7% margin.
  • Decoction pieces. Prepared raw herbs, with revenue up 0.6% and a thin margin of 25.1%.
  • Herb integration. The group exited low-margin trading, so revenue dropped 40.2%.
  • Health products. “Great health” items fell 17.2%, which shows that consumer wellness is not a free ride.

Centralized procurement, meaning state-organized bulk buying at low prices, is the main reason for pressure.. It moved from western drugs to TCM granules, so prices fell and competition increased.

A modern, adapted tradition

Traditions also adapt to modern practice. Some substances are no longer used, for instance those derived from endangered species, which are replaced by remedies with similar actions and less environmental cost. Quality control, standardized extracts, clinical trials and traceable sourcing are now part of the business.

The state also supports TCM as a policy goal, through hospitals, insurance reimbursement and exports. At the same time, rules on herb quality, pesticide residues and claims are stricter, and companies without strong sourcing are exposed.

What it means for foreign companies

The market is open in some areas and closed in others. Foreign firms can sell herbal-based health products and ingredients, and some partner with local groups to reach customers. Registering a product as a medicine is much harder, and requires clinical data and a local license holder.

Foreign interest also focuses on the opposite direction: bringing Chinese formulas abroad, where they are regulated as food supplements or herbal products, and where claims are limited.

Consumers and the health market

Chinese consumers use herbal products in several ways. Some follow a doctor’s prescription in a hospital, others buy ready-made patent medicines at pharmacies, and a growing group buys food-like products such as herbal teas, tonics and supplements online. Each route has its own rules, price level and trust factors.

Younger consumers, in particular, treat herbal products as a lifestyle choice. They look for convenient formats, such as small sachets, gummies or ready-to-drink bottles, and for clear explanations in plain language. A traditional name still gives credibility, but the packaging, the story and the proof of quality need a modern form.

This is also why the old brands with long histories are moving to online channels and cooperating with hospitals and universities. A company that can show lab tests, clinical studies and a safe supply chain gets a premium over those that rely on tradition alone.

Daxue Take

We would consider these options, with their limits:

  • If the company sells health or wellness products, use herbal ingredients as a story, but support every claim with data. The 17.2% fall in health products shows that consumers are choosy.
  • If the company is an ingredient supplier, focus on traceability and standard extracts, which buyers now ask for.
  • If the company wants to enter medicines, partner with an established local group and expect years of work.
  • If the company is an investor, read the segment margins. A group with branded finished drugs is better protected from price cuts than one that depends on commodity granules.

The limit is policy risk. Procurement rules can change quickly, and one new list can cut prices for a whole category.

What to watch next

  • Whether centralized procurement spreads to more TCM products.
  • Recovery of margins at granule makers.
  • Growth of branded finished drugs and patent protection.
  • Our related work on bio-cosmetics, elderly care and the make-up market.

FAQ

What is Traditional Chinese Medicine?
A health system based on Qi, Yin and Yang, using herbs and extracts in formulas, with about 5,000 years of use.

How many formulas exist?
More than 400 common formulas, each with 4 to 12 herbs.

Is the herbal medicine industry growing?
Not evenly. China TCM Holdings’ revenue fell 10.7% in 2025 because of procurement pressure.

Can foreign companies sell herbal medicine in China?
Yes for ingredients and health products, but registering a medicine is much harder.

Which products earn the best margin?
Branded finished drugs, at about 66.7% gross margin in the leading group’s case.

About Daxue Consulting

Daxue Consulting is a market research and strategy consulting firm focused on China, founded in Beijing in 2012, with offices in Shanghai, Beijing and Hong Kong. We have delivered more than 800 projects for international brands. To discuss traditional Chinese medicine and herbal health products, see our market research services or contact our team.

Related articles

Search